explore -WSS

explore

author：hotspot 2025-10-02 22:30:12 - browse：5

Elizabeth Warren speaks behind a podium with a sign that reads "ABORTION RIGHTS FOR ALL" — Sen. Elizabeth Warren (D-Mass.) J. Scott Applewhite/AP

WASHINGTON — Sen. Elizabeth Warren (D-Mass.) is launching a fresh round of questioning on states’ limits to abortion rights as a battle on medication abortion hangs in the balance at a federal court.

Warren and three other Democratic senators sent letters late last week to five major health care worker and pharmacy groups interrogating how last year’s U.S. Supreme Court decision reversing national abortion rights has affected health care access and providers’ treatment of patients.

It’s not the first time the Massachusetts Democrat has aimed questions at these organizations, which include the American Medical Association, Physicians for Reproductive Health, National Nurses United, the American Pharmacists Association, and the American Hospital Association. She asked the same set of groups last summer how the U.S. Supreme Court’s overturn of Roe v. Wade impacted women’s health care, and reported in October that the groups warned about “diminished access” to pregnancy care and abortion bans that “will exacerbate existing health inequities.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout Newsletter: Merck, J&J, and long Covid

WSS

Francis Collins on trust in science and how Covid communications failed

Dewpoint Therapeutics lays off staff after losing partnerships

Gene therapy has helped boys walk. Can scientists keep it that way?

Readout Newsletter: Merck, J&J, and long Covid

Do masks work? RCTs can't tell us

Cloning humans is technically possible. It's curious no one has tried

hotspot

explore

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA clears AI tool for detecting skin cancer

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana cuts profit projections as Medicare Advantage costs soar

Cancer drug shortages should be causing more outrage

The tragedy of Johnson & Johnson’s Covid vaccine

New air purifier tech could be key to improving indoor air quality

Colonoscopy at 40? Study finds a possible benefit

Psychedelics group wrestles with new pharma identity

Cloning humans is technically possible. It's curious no one has tried

focus

AI generated plenty of interest at JPM but not a lot of trust

Research misconduct: Proposed new rules face resistance

Test for long Covid? Researchers find new clue in blood samples

Independent physicians launch a new lobbying group

How digital therapeutics firms are pivoting after Pear's bankruptcy

The surgeon had a dilemma only a Nazi medical text could resolve

entertainment

focus

knowledge

hotspot